Scott Drutman

Scott is an oncologist physician scientist who is passionate about translating scientific discoveries into treatments for cancer patients.

Prior to joining Volastra, Scott worked in oncology clinical development at Regeneron Pharmaceuticals in both early and late development across multiple assets, including leading a first in class clinical program for REGN7075 (EGFRxCD28 bispecific) across multiple tumor types. In addition to driving clinical programs, Scott simultaneously worked in business development, where he was responsible for scientific and clinical diligence and strategy for the solid tumor oncology program.

Prior to Regeneron, Scott was an Instructor at The Rockefeller University, where his research program focused on immunology and human genetics.

Scott completed his postdoctoral fellowship at The Rockefeller University, his medical oncology clinical fellowship and additional training in early phase immuno-oncology at Memorial Sloan Kettering Cancer Center, and his internal medicine residency at New York-Presbyterian/Weill Cornell

He received an undergraduate degree from Reed College, an M.D./Ph.D. from NYU School of Medicine, and an M.S. in clinical and translational investigation from The Rockefeller University.